Investment Analysts’ Weekly Ratings Changes for Oncology Institute (STLN)

A number of research firms have changed their ratings and price targets for Oncology Institute (NASDAQ: STLN):

  • 11/6/2026 – Oncology Institute had its price target lowered by Lake Street Capital from $10.00 to $8.00. They now have a “buy” rating on the stock.
  • 11/6/2026 – Oncology Institute had its “buy” rating reaffirmed by B. Riley Financial. They now have a $10.00 price target on the stock, down from $11.00.
  • 11/6/2026 – Oncology Institute had its price target raised by BTIG Research from $9.00 to $10.00. They now have a “buy” rating on the stock.
  • 11/3/2026 – Oncology Institute had its “sell (d-)” rating reaffirmed by Weiss Ratings.
  • 10/14/2026 – Oncology Institute had its price target raised by Needham & Company LLC from $7.00 to $9.00. They now have a “buy” rating on the stock.

Oncology Institute Stock Performance

STLN stock opened at $3.20 on Thursday. Oncology Institute, Inc. has a fifty-two week low of $2.32 and a fifty-two week high of $7.13. The company has a market capitalization of $326.37 million, a P/E ratio of -11.03 and a beta of 0.44. The firm has a 50-day moving average price of $6.06.

Oncology Institute (NASDAQ:STLN – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $169.77 million during the quarter. On average, sell-side analysts anticipate that Oncology Institute, Inc. will post -0.27 EPS for the current year.

Insider Activity at Oncology Institute

In other Oncology Institute news, major shareholder Jorey Chernett bought 48,294 shares of Oncology Institute stock in a transaction on Monday, November 9th. The shares were acquired at an average price of $3.65 per share, for a total transaction of $176,273.10. Following the completion of the purchase, the insider directly owned 7,858,091 shares in the company, valued at approximately $28,682,032.15. This trade represents a 0.62% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Brad Hively sold 298,853 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $6.51, for a total transaction of $1,945,533.03. Following the transaction, the director directly owned 411,976 shares in the company, valued at approximately $2,681,963.76. This trade represents a 42.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 4.40% of the company’s stock.

The Oncology Institute is a physician-led provider of cancer care. Its services include medical oncology and hematology consultations, cancer treatment and infusion services, pharmacy support, and access to clinical trials. The company combines community-based clinics with care coordination and value-based care programs intended to support patients throughout treatment. It serves patients in several U.S. states, including California, Nevada, Arizona, and Florida. Founded in 2007, The Oncology Institute has expanded its network of oncology clinics and related services to provide cancer care closer to where patients live.

Read More

Receive News & Ratings for Oncology Institute Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncology Institute Inc and related companies with MarketBeat.com's FREE daily email newsletter.